Which has preferable earnings & valuation, ARTV or KARD?

Kardigan has lower revenue, but higher earnings than Artiva Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artiva Biotherapeutics $250K 1,683.77 -$83.86M -$3.30 N/A Kardigan N/A N/A N/A N/A N/A

Is ARTV or KARD more profitable?

Kardigan's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Kardigan N/A N/A N/A

Does the media prefer ARTV or KARD?

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Kardigan. MarketBeat recorded 2 mentions for Artiva Biotherapeutics and 1 mentions for Kardigan. Kardigan's average media sentiment score of 0.95 beat Artiva Biotherapeutics' score of 0.69 indicating that Kardigan is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARTV or RXRX?

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 2 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.69 beat Recursion Pharmaceuticals' score of 0.57 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TSHA or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.19% -41.84% Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media favor TSHA or ARTV?

In the previous week, Taysha Gene Therapies had 2 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Taysha Gene Therapies and 2 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.69 beat Taysha Gene Therapies' score of 0.59 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARTV or IMCR?

In the previous week, Immunocore had 2 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Immunocore and 2 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.69 beat Immunocore's score of 0.57 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FBRX or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Artiva Biotherapeutics N/A -53.86% -48.16%

Artiva Biotherapeutics (ARTV) Competitors

$8.61 +0.17 (+2.01%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.65 +0.04 (+0.49%)

As of 09/18/2026 07:30 PM Eastern

Compare

ARTV vs. KARD, RXRX, TSHA, IMCR, and FBRX

Should you buy Artiva Biotherapeutics stock or one of its competitors? Artiva Biotherapeutics's main competitors and comparable companies include Kardigan (KARD), Recursion Pharmaceuticals (RXRX), Taysha Gene Therapies (TSHA), Immunocore (IMCR), and Forte Biosciences (FBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Artiva Biotherapeutics compare to Kardigan?

Artiva Biotherapeutics (NASDAQ:ARTV) and Kardigan (NASDAQ:KARD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Kardigan's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Kardigan	N/A	N/A	N/A

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Kardigan. MarketBeat recorded 2 mentions for Artiva Biotherapeutics and 1 mentions for Kardigan. Kardigan's average media sentiment score of 0.95 beat Artiva Biotherapeutics' score of 0.69 indicating that Kardigan is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 352.96%. Kardigan has a consensus price target of $42.25, indicating a potential upside of 153.91%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Artiva Biotherapeutics is more favorable than Kardigan.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kardigan has lower revenue, but higher earnings than Artiva Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,683.77	-$83.86M	-$3.30	N/A
Kardigan	N/A	N/A	N/A	N/A	N/A

Summary

Artiva Biotherapeutics beats Kardigan on 5 of the 8 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Recursion Pharmaceuticals?

Artiva Biotherapeutics (NASDAQ:ARTV) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 2 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.69 beat Recursion Pharmaceuticals' score of 0.57 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artiva Biotherapeutics presently has a consensus price target of $39.00, suggesting a potential upside of 352.96%. Recursion Pharmaceuticals has a consensus price target of $8.06, suggesting a potential upside of 110.44%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Artiva Biotherapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Artiva Biotherapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,683.77	-$83.86M	-$3.30	N/A
Recursion Pharmaceuticals	$74.68M	27.46	-$644.76M	-$1.04	N/A

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Artiva Biotherapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Artiva Biotherapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Summary

Artiva Biotherapeutics beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Artiva Biotherapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	167.42	-$109M	-$0.42	N/A
Artiva Biotherapeutics	$250K	1,683.77	-$83.86M	-$3.30	N/A

In the previous week, Taysha Gene Therapies had 2 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Taysha Gene Therapies and 2 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.69 beat Taysha Gene Therapies' score of 0.59 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Taysha Gene Therapies presently has a consensus target price of $12.77, suggesting a potential upside of 154.37%. Artiva Biotherapeutics has a consensus target price of $39.00, suggesting a potential upside of 352.96%. Given Artiva Biotherapeutics' higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Artiva Biotherapeutics' return on equity of -53.86% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

Summary

Taysha Gene Therapies beats Artiva Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Immunocore?

Artiva Biotherapeutics (NASDAQ:ARTV) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Artiva Biotherapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Artiva Biotherapeutics. Immunocore is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,683.77	-$83.86M	-$3.30	N/A
Immunocore	$400.02M	4.12	-$35.51M	-$0.37	N/A

Artiva Biotherapeutics has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Immunocore	-4.20%	-4.54%	-1.66%

Artiva Biotherapeutics presently has a consensus price target of $39.00, indicating a potential upside of 352.96%. Immunocore has a consensus price target of $56.38, indicating a potential upside of 76.17%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Artiva Biotherapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Immunocore had 2 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Immunocore and 2 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.69 beat Immunocore's score of 0.57 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Immunocore shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 10.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Immunocore beats Artiva Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Forte Biosciences has higher earnings, but lower revenue than Artiva Biotherapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Artiva Biotherapeutics	$250K	1,683.77	-$83.86M	-$3.30	N/A

Artiva Biotherapeutics' return on equity of -53.86% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Forte Biosciences presently has a consensus price target of $71.67, suggesting a potential downside of 6.91%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 352.96%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Artiva Biotherapeutics had 2 more articles in the media than Forte Biosciences. MarketBeat recorded 2 mentions for Artiva Biotherapeutics and 0 mentions for Forte Biosciences. Artiva Biotherapeutics' average media sentiment score of 0.69 beat Forte Biosciences' score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Forte Biosciences	Neutral
Artiva Biotherapeutics	Positive

Summary

Artiva Biotherapeutics beats Forte Biosciences on 11 of the 15 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTV vs. The Competition

Export

Metric	Artiva Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$420.94M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-2.61	14.23	274.93	25.38
Price / Sales	1,683.77	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	1.92	15.45	10.46	6.33
Net Income	-$83.86M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-15.75%	-1.21%	0.59%	1.12%
1 Month Performance	-22.71%	-3.29%	-1.74%	-2.39%
1 Year Performance	198.96%	37.74%	18.13%	5.35%

Artiva Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTV Artiva Biotherapeutics	3.3669 of 5 stars	$8.61 +2.0%	$39.00 +353.0%	+199.0%	$420.94M	$250K	N/A	115	High Trading Volume
KARD Kardigan	3.7373 of 5 stars	$18.56 -2.6%	$42.25 +127.6%	N/A	$1.74B	N/A	N/A	241
RXRX Recursion Pharmaceuticals	1.7573 of 5 stars	$3.24 -5.0%	$8.06 +148.8%	-22.0%	$1.73B	$53.94M	N/A	600	News Coverage Options Volume
TSHA Taysha Gene Therapies	3.1704 of 5 stars	$5.06 +1.0%	$12.77 +152.4%	+77.4%	$1.65B	$5.49M	N/A	99	News Coverage Analyst Forecast
IMCR Immunocore	3.5952 of 5 stars	$31.77 -2.1%	$56.38 +77.4%	-1.8%	$1.64B	$430.78M	N/A	524

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTV) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. KARD, RXRX, TSHA, IMCR, and FBRX

How does Artiva Biotherapeutics compare to Kardigan?

Summary

How does Artiva Biotherapeutics compare to Recursion Pharmaceuticals?

Summary

How does Artiva Biotherapeutics compare to Taysha Gene Therapies?

Summary

How does Artiva Biotherapeutics compare to Immunocore?

Summary

How does Artiva Biotherapeutics compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. KARD, RXRX, TSHA, IMCR, and FBRX

How does Artiva Biotherapeutics compare to Kardigan?

Is ARTV or KARD more profitable?

Does the media prefer ARTV or KARD?

Do analysts prefer ARTV or KARD?

Which has preferable earnings & valuation, ARTV or KARD?

Summary

How does Artiva Biotherapeutics compare to Recursion Pharmaceuticals?

Does the media favor ARTV or RXRX?

Do analysts recommend ARTV or RXRX?

Which has better valuation & earnings, ARTV or RXRX?

Do insiders and institutionals have more ownership in ARTV or RXRX?

Which has more volatility and risk, ARTV or RXRX?

Is ARTV or RXRX more profitable?

Summary

How does Artiva Biotherapeutics compare to Taysha Gene Therapies?

Which has higher earnings and valuation, TSHA or ARTV?

Does the media favor TSHA or ARTV?

Which has more volatility and risk, TSHA or ARTV?

Do analysts prefer TSHA or ARTV?

Do institutionals and insiders hold more shares of TSHA or ARTV?

Is TSHA or ARTV more profitable?

Summary

How does Artiva Biotherapeutics compare to Immunocore?

Which has more volatility and risk, ARTV or IMCR?

Which has stronger earnings & valuation, ARTV or IMCR?

Is ARTV or IMCR more profitable?

Do analysts recommend ARTV or IMCR?

Does the media refer more to ARTV or IMCR?

Do institutionals & insiders hold more shares of ARTV or IMCR?

Summary

How does Artiva Biotherapeutics compare to Forte Biosciences?

Which has more volatility and risk, FBRX or ARTV?

Which has better valuation & earnings, FBRX or ARTV?

Is FBRX or ARTV more profitable?

Do institutionals and insiders hold more shares of FBRX or ARTV?

Do analysts prefer FBRX or ARTV?

Does the media refer more to FBRX or ARTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools